CAS No. : 22368-21-4
|Size||Stock||Price||Quantity||Add to Cart||Quotation Online|
|Cat. No. :||CS-5407|
|CAS No. :||22368-21-4|
|M. Wt. :||344.32|
|Solubility:||10 mM in DMSO|
Eupatilin, a flavone derived from Artemisia princepsPampanini, has various pharmacological activities, including antioxidant, anti-tumor, and anti-inflammatory capacities. IC50 value: Target: In vitro: The present study aimed to investigate the effects of eupatilin on this malignant bone tumor, using the U-2 OS cell line. The experimental results revealed that eupatilin inhibited U-2 OS cell growth in a concentration-dependent manner and induced G2/M phase cell cycle arrest and apoptosis . Eupatilin reduced U937 cells adhesion to TNF-α-stimulated HUVECs and attenuated TNF-α-induced the expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in HUVECs, as well as the production of intracellular reactive oxygen species (ROS). Moreover, eupatilininhibits TNF-α-induced phosphorylation of NF-kB p65 and MAPKs in HUVECs . In vivo:
Protocol:Kinase Assay: Enzyme assay  The activities of caspase-3, -8 and -9 were evaluated using a caspase colorimetric assay kit. U-2 OS cells were seeded in 12-well culture plates at a density of 2×105 cells/well prior to incubation with eupatilin for 48 h. The cells were then harvested, lysed with lysis buffer for ~5 min in an ice bath and then centrifuged at 10,000 × g for 10 min. Subsequently, the reaction buffer was added to the supernatant solutions containing the proteins (100 μg). Caspase-3, -8 and -9 colorimetric substrates (5 μl each) were then added for 2 h at 37°C in a CO2incubator, prior to quantification of the optical density (OD) of the mixture at 405 nm using a spectrophotometer. Cell Assay: Cell assay  The viability of U-2 OS cells was determined using an MTT assay. U-2 OS cells were seeded at a density of 5×104 cells/well in 96-well culture plates. Each well contained 100 μl medium supplemented with 10% FCS, and the cells were incubated at 37°C for 24 h prior to treatment with various concentrations of eupatilin. Following 24 h of incubation, the medium was removed and replaced with 10% FCS containing various concentrations of eupatilin (0, 50, 100, 200 and 400 μg/ml) and incubated at 37°C for 96 h. Subsequently, 50 μl MTT solution was added to each well and incubated for a further 4 h as described previously (22). The formazan crystals obtained were dissolved in 100 μl DMSO and the absorbance was recorded using an ELISA microplate reader at a wavelength of 570 nm.
Yu K, et al. Eupatilin protects against tumor necrosis factor-α-mediated inflammation inhuman umbilical vein endothelial cells. Int J Clin Exp Med. 2015 Dec 15;8(12):22191-7.
Jeong JH, et al. Eupatilin Exerts Antinociceptive and Chondroprotective Properties in a Rat Model of Osteoarthritis by Downregulating Oxidative Damage and Catabolic Activity in Chondrocytes. PLoS One. 2015 Jun 17;10(6):e0130882.
Li YY, et al. Application of eupatilin in the treatment of osteosarcoma. Oncol Lett. 2015 Oct;10(4):2505-2510.
- Select Batch :
- CS-5407 19674
|Tags:Eupatilin supplier,Eupatilin purchase,Eupatilin manufacturer,Eupatilin sigma,Eupatilin distributor,cost,Eupatilin buy,Eupatilin for sale|